rs41267501

Variant summary

Our verdict is Benign. The variant received -16 ACMG points: 0P and 16B. BP6_Very_StrongBS1BS2

The NM_000069.3(CACNA1S):​c.3053+13T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0166 in 1,614,082 control chromosomes in the GnomAD database, including 297 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.013 ( 19 hom., cov: 33)
Exomes 𝑓: 0.017 ( 278 hom. )

Consequence

CACNA1S
NM_000069.3 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:13

Conservation

PhyloP100: 0.979

Publications

3 publications found
Variant links:
Genes affected
CACNA1S (HGNC:1397): (calcium voltage-gated channel subunit alpha1 S) This gene encodes one of the five subunits of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle cells. Mutations in this gene have been associated with hypokalemic periodic paralysis, thyrotoxic periodic paralysis and malignant hyperthermia susceptibility. [provided by RefSeq, Jul 2008]
CACNA1S Gene-Disease associations (from GenCC):
  • congenital myopathy 18
    Inheritance: AD, AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • hypokalemic periodic paralysis, type 1
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
  • malignant hyperthermia, susceptibility to, 5
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • congenital myopathy
    Inheritance: SD, AR, AD Classification: STRONG Submitted by: Illumina, Genomics England PanelApp
  • hypokalemic periodic paralysis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -16 ACMG points.

BP6
Variant 1-201061931-A-G is Benign according to our data. Variant chr1-201061931-A-G is described in ClinVar as Benign. ClinVar VariationId is 254824.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.0134 (2038/152350) while in subpopulation SAS AF = 0.0377 (182/4826). AF 95% confidence interval is 0.0332. There are 19 homozygotes in GnomAd4. There are 1050 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 19 AD,AR,SD gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CACNA1SNM_000069.3 linkc.3053+13T>C intron_variant Intron 24 of 43 ENST00000362061.4 NP_000060.2 Q13698
CACNA1SXM_005245478.4 linkc.3053+13T>C intron_variant Intron 24 of 42 XP_005245535.1 B1ALM3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CACNA1SENST00000362061.4 linkc.3053+13T>C intron_variant Intron 24 of 43 1 NM_000069.3 ENSP00000355192.3 Q13698

Frequencies

GnomAD3 genomes
AF:
0.0134
AC:
2039
AN:
152232
Hom.:
19
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00292
Gnomad AMI
AF:
0.0428
Gnomad AMR
AF:
0.0126
Gnomad ASJ
AF:
0.0219
Gnomad EAS
AF:
0.000192
Gnomad SAS
AF:
0.0377
Gnomad FIN
AF:
0.0232
Gnomad MID
AF:
0.0380
Gnomad NFE
AF:
0.0167
Gnomad OTH
AF:
0.0158
GnomAD2 exomes
AF:
0.0178
AC:
4483
AN:
251250
AF XY:
0.0195
show subpopulations
Gnomad AFR exome
AF:
0.00308
Gnomad AMR exome
AF:
0.00796
Gnomad ASJ exome
AF:
0.0253
Gnomad EAS exome
AF:
0.000272
Gnomad FIN exome
AF:
0.0252
Gnomad NFE exome
AF:
0.0184
Gnomad OTH exome
AF:
0.0209
GnomAD4 exome
AF:
0.0170
AC:
24836
AN:
1461732
Hom.:
278
Cov.:
33
AF XY:
0.0179
AC XY:
13019
AN XY:
727180
show subpopulations
African (AFR)
AF:
0.00290
AC:
97
AN:
33478
American (AMR)
AF:
0.00861
AC:
385
AN:
44718
Ashkenazi Jewish (ASJ)
AF:
0.0234
AC:
611
AN:
26134
East Asian (EAS)
AF:
0.000327
AC:
13
AN:
39700
South Asian (SAS)
AF:
0.0360
AC:
3102
AN:
86254
European-Finnish (FIN)
AF:
0.0231
AC:
1231
AN:
53366
Middle Eastern (MID)
AF:
0.0411
AC:
237
AN:
5768
European-Non Finnish (NFE)
AF:
0.0163
AC:
18123
AN:
1111924
Other (OTH)
AF:
0.0172
AC:
1037
AN:
60390
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.487
Heterozygous variant carriers
0
1432
2865
4297
5730
7162
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
642
1284
1926
2568
3210
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0134
AC:
2038
AN:
152350
Hom.:
19
Cov.:
33
AF XY:
0.0141
AC XY:
1050
AN XY:
74494
show subpopulations
African (AFR)
AF:
0.00291
AC:
121
AN:
41588
American (AMR)
AF:
0.0125
AC:
192
AN:
15304
Ashkenazi Jewish (ASJ)
AF:
0.0219
AC:
76
AN:
3472
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5190
South Asian (SAS)
AF:
0.0377
AC:
182
AN:
4826
European-Finnish (FIN)
AF:
0.0232
AC:
246
AN:
10624
Middle Eastern (MID)
AF:
0.0374
AC:
11
AN:
294
European-Non Finnish (NFE)
AF:
0.0167
AC:
1137
AN:
68024
Other (OTH)
AF:
0.0156
AC:
33
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.496
Heterozygous variant carriers
0
104
208
313
417
521
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
28
56
84
112
140
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0145
Hom.:
4
Bravo
AF:
0.0117
Asia WGS
AF:
0.0220
AC:
77
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:5
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 13, 2016
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Hypokalemic periodic paralysis, type 1 Benign:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Apr 11, 2023
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Nov 06, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Congenital myopathy 18 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Thyrotoxic periodic paralysis, susceptibility to, 1 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Malignant hyperthermia, susceptibility to, 5;C3714580:Hypokalemic periodic paralysis, type 1 Benign:1
Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Malignant hyperthermia, susceptibility to, 5 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.86
CADD
Benign
6.1
DANN
Benign
0.29
PhyloP100
0.98
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.23
Details are displayed if max score is > 0.2
DS_DG_spliceai
0.23
Position offset: -30

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs41267501; hg19: chr1-201031059; COSMIC: COSV107453886; API